CompletedPhase 2NCT02658487
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Studying Acute myeloid leukaemia with myelodysplasia-related features
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Principal Investigator
- Sanjay Mohan, MDVanderbilt-Ingram Cancer Center
- Intervention
- Cytarabine(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2024
Study locations (3)
- Yale University, New Haven, Connecticut, United States
- Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02658487 on ClinicalTrials.govOther trials for Acute myeloid leukaemia with myelodysplasia-related features
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04802161Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesNational Cancer Institute (NCI)
- RECRUITINGNCT01210274Characterization of the Mechanisms of Resistance to AzacitidineCentre Hospitalier Universitaire de Nice
See all trials for Acute myeloid leukaemia with myelodysplasia-related features →